PCN Inspects NBRDA Facility Ahead of La_Shipson Pharmaceutical’s Pilot Drug Production Phase

By Iyojo Ameh

The Pharmacists Council of Nigeria (PCN) has conducted a thorough inspection of laboratory and production facilities at the National Biotechnology Research Development Agency (NBRDA) in Abuja, ahead of La_Shipson Pharmaceutical Limited’s plan to commence pilot pharmaceutical drug production.

The inspection is part of the regulatory requirements needed before the start of local drug manufacturing by La_Shipson Pharmaceutical Limited. The facilities inspected are expected to support the company’s vision of producing affordable, high-quality medicines and vaccines locally.

The PCN team was received by La_Shipson’s Chief Executive Officer, Hon. Moses Godia Shipi, executives of the company, and staff of NBRDA.

The inspection covered a wide range of advanced laboratories and equipment crucial for drug research and development. Among the facilities evaluated were:
Molecular Biotechnology Laboratories, General Research Laboratories, Molecular Diagnostics Laboratory and Gene Cloning, Protein Expression and Purification Laboratory.
Plus other infrastructure key to pharmaceutical innovation and regulatory compliance.

La_Shipson’s planned establishment of a Gene Cloning, Protein Expression and Purification Laboratory stands out as a major component of the initiative, reinforcing the company’s focus on cutting-edge biotechnology applications in drug manufacturing.

Speaking during the inspection, Hon. Shipi commended the PCN for its thoroughness and professionalism. He also praised the NBRDA for its strong partnership and commitment to advancing Nigeria’s pharmaceutical capabilities.

“What we are witnessing is not just a regulatory requirement; it is a reaffirmation of our collective resolve to make Nigeria self-reliant in the production of safe and affordable medicines,” Shipi said.
“We are determined to build a future where science meets compassion—where our people no longer rely solely on imports for life-saving drugs.”

Officials of NBRDA expressed their readiness to support La_Shipson with scientific and technical expertise required to achieve its goals. They reiterated their commitment to leveraging biotechnology for addressing Nigeria’s pressing health challenges and boosting its presence in the global pharmaceutical space.

The inspection comes at a time when Nigeria is intensifying efforts to strengthen its healthcare sector through innovation and local capacity building. The collaboration between La_Shipson Pharmaceutical and NBRDA is seen as a bold step toward transforming Nigeria into a hub for pharmaceutical research, development, and production in Africa.

La_Shipson Pharmaceutical Limited is an indigenous forward-looking pharmaceutical firm dedicated to developing and producing high-quality, affordable medicines and vaccines tailored to the healthcare needs of Nigerians and the African continent.